SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (ART)
PET Imaging of Synaptic Density Combined With Neuroimmunologic Measures to Reveal Mechanisms of HIV Neuropathogenesis During ART
Sponsor: National Institute of Mental Health (NIMH)
Listed as NCT05586581, this PHASE1/PHASE2 trial focuses on HIV Associated Neurocognitive Disorder and HIV Dementia and remains actively recruiting participants. Sponsored by National Institute of Mental Health (NIMH), it has been updated 7 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Mental Health (NIMH)
- National Institutes of Health (NIH)
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .